Compare IPCA Labs with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs LUPIN - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS LUPIN IPCA LABS/
LUPIN
 
P/E (TTM) x 31.0 -128.5 - View Chart
P/BV x 6.3 2.9 219.2% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   LUPIN
EQUITY SHARE DATA
    IPCA LABS
Mar-19
LUPIN
Mar-19
IPCA LABS/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,042986 105.7%   
Low Rs590720 81.9%   
Sales per share (Unadj.) Rs298.6369.5 80.8%  
Earnings per share (Unadj.) Rs35.013.4 261.1%  
Cash flow per share (Unadj.) Rs49.437.4 132.2%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs247.1303.7 81.4%  
Shares outstanding (eoy) m126.35452.49 27.9%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.72.3 118.3%   
Avg P/E ratio x23.363.6 36.6%  
P/CF ratio (eoy) x16.522.8 72.3%  
Price / Book Value ratio x3.32.8 117.5%  
Dividend payout %8.60-   
Avg Mkt Cap Rs m103,108386,064 26.7%   
No. of employees `00013.417.7 76.0%   
Total wages/salary Rs m7,87431,513 25.0%   
Avg. sales/employee Rs Th2,807.09,453.8 29.7%   
Avg. wages/employee Rs Th585.81,782.0 32.9%   
Avg. net profit/employee Rs Th329.0343.0 95.9%   
INCOME DATA
Net Sales Rs m37,732167,182 22.6%  
Other income Rs m5773,640 15.8%   
Total revenues Rs m38,309170,822 22.4%   
Gross profit Rs m6,90128,822 23.9%  
Depreciation Rs m1,82410,850 16.8%   
Interest Rs m1893,078 6.1%   
Profit before tax Rs m5,46518,534 29.5%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m1,0429,017 11.6%   
Profit after tax Rs m4,4226,066 72.9%  
Gross profit margin %18.317.2 106.1%  
Effective tax rate %19.148.7 39.2%   
Net profit margin %11.73.6 323.0%  
BALANCE SHEET DATA
Current assets Rs m23,778138,536 17.2%   
Current liabilities Rs m10,97561,299 17.9%   
Net working cap to sales %33.946.2 73.4%  
Current ratio x2.22.3 95.9%  
Inventory Days Days10484 123.9%  
Debtors Days Days66112 58.6%  
Net fixed assets Rs m20,368127,516 16.0%   
Share capital Rs m253905 27.9%   
"Free" reserves Rs m30,971136,517 22.7%   
Net worth Rs m31,224137,422 22.7%   
Long term debt Rs m1,40966,417 2.1%   
Total assets Rs m45,507279,494 16.3%  
Interest coverage x30.07.0 426.7%   
Debt to equity ratio x00.5 9.3%  
Sales to assets ratio x0.80.6 138.6%   
Return on assets %10.13.3 309.7%  
Return on equity %14.24.4 320.9%  
Return on capital %17.38.9 194.5%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30859,414 29.1%   
Fx outflow Rs m6,26622,282 28.1%   
Net fx Rs m11,04237,132 29.7%   
CASH FLOW
From Operations Rs m4,92316,660 29.5%  
From Investments Rs m-1,563-32,825 4.8%  
From Financial Activity Rs m-1,8327,441 -24.6%  
Net Cashflow Rs m1,528-8,724 -17.5%  

Share Holding

Indian Promoters % 45.9 46.6 98.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.4 11.3 100.9%  
FIIs % 25.3 31.9 79.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.1 172.3%  
Shareholders   36,892 98,259 37.5%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   AJANTA PHARMA  GLENMARK PHARMA  AUROBINDO PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 522 Points Higher(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.

Related Views on News

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

Why We Picked This Smallcap Stock for a Post Coronavirus World(Profit Hunter)

May 28, 2020

Covid-19 has made it a survival of the fittest race for many companies. The ones that can adapt will thrive in a post crisis world.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 2, 2020 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS